Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts

Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to bolster its E.U. hub.
Catalent has acquired Promethera’s Hepatic Cell Therapy Support SA (HCTS) subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. The financial terms of the deal were not disclosed.
The pickup will help Catalent move into plasmid DNA production, complementing its recent purchase of Delphi Genetics, located at Catalent’s growing campus in Gosselies. That buyout added a 17,000-square-foot facility.
The HCTS site comes equipped with existing cleanroom infrastructure, process development, quality control laboratories, and warehouse space and will be equipped to provide pDNA manufacturing up to a 500-liter scale, Catalent said.
Catalent expects to start outfitting the facility immediately and plans to add more than 200 jobs at the facility, the company said.
Price Action: CTLT shares are down 1.35% at $105.04 during market trading hours on the last check Thursday.